AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.

The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

Robert Love is a neuroscientist who often shares health advice with his followers online. He recently turned his attention to arthritis and inflammation ...

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum.

A new Swedish study has, for the first time, shown a link between rheumatoid arthritis (RA) and cognitive decline in dementia ...

Turmeric shots are a wellness drink that may offer many health benefits for their antioxidant and anti-inflammatory effects, ...

A team of scientists from the University of Colorado has made an important discovery that could change how we understand and ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Discover how high-content imaging identifies drug responses and disease activity in rheumatoid arthritis, paving the way for personalized treatments.

Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.